Month: September 2026

On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital.

Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme.

The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulation. The buy-back is carried out on Nasdaq Copenhagen at market price and in accordance with the authorization granted by the general meeting, Nasdaq Copenhagen’s rules for issuers, as well as Gabriel Holding A/S’ internal rules on insider matters and handling of inside information.

The following transactions have been carried out under the programme during the period below:

	Number of shares	Average purchase price	Transaction value in DKK
Treasury shares before start of programme	55.109
Accumulated under the programme in accordance with the latest announcement	6,650	272.28	1,810,644
Monday, 7 September 2026	65	232.00	15,080
Tuesday, 8 September 2026	65	226.46	14,720
Wednesday, 9 September 2026	75	235.73	17,680
Thursday, 10 September 2026	80	231.50	18,520
Friday, 11 September 2026	80	228.50	18,280
Accumulated under the programme in accordance with the above transactions	7,015	270.12	1,894,924

With the above transactions, the company’s holding of treasury shares amounts to 62,124 shares, corresponding to 3.29% of the total number of issued shares of 1,890,000.

Inquiries and further information:
CEO Anders Hedegaard Petersen, phone +45 9630 3117

Appendix

Detailed data on share buy-back transactions is enclosed in accordance with Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures, Article 2. All transactions have been carried out by Danske Bank A/S on behalf of Gabriel Holding A/S.

Volume	Price	Venue	Time – GMT	Time – CET
35	232	XCSE	20260907 11:01:58.180872 +0100s	20260907 12:01:58.180872
30	232	XCSE	20260907 15:17:01.936078 +0100s	20260907 16:17:01.936078
10	226	XCSE	20260908 11:46:55.888102 +0100s	20260908 12:46:55.888102
40	226	XCSE	20260908 11:46:55.888102 +0100s	20260908 12:46:55.888102
15	228	XCSE	20260908 14:44:44.864907 +0100s	20260908 15:44:44.864907
20	236	XCSE	20260909 08:06:50.075971 +0100s	20260909 9:06:50.075971
15	236	XCSE	20260909 08:26:25.473327 +0100s	20260909 9:26:25.473327
10	234	XCSE	20260909 08:33:46.476233 +0100s	20260909 9:33:46.476233
20	236	XCSE	20260909 12:34:11.410570 +0100s	20260909 13:34:11.410570
10	236	XCSE	20260909 13:01:13.922775 +0100s	20260909 14:01:13.922775
20	230	XCSE	20260910 10:18:03.854284 +0100s	20260910 11:18:03.854284
40	232	XCSE	20260910 12:07:32.792097 +0100s	20260910 13:07:32.792097
20	232	XCSE	20260910 13:49:56.646424 +0100s	20260910 14:49:56.646424
40	230	XCSE	20260911 08:54:10.629286 +0100s	20260911 9:54:10.629286
20	226	XCSE	20260911 11:37:27.065596 +0100s	20260911 12:37:27.065596
20	228	XCSE	20260911 15:38:56.560102 +0100s	20260911 16:38:56.560102

This is a translation of the original Danish text. In the event of discrepancies between the Danish and English texts, the Danish version shall prevail.

Attachment

• Gabriel Holding AS – Announcement no 28 – share buy back week 37

• Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively
• Transformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel development
• Realignment of the operating model targeting Cellectis cash runway extension into H2 2028
• Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.

A differentiated in vivo Gene Editing pipeline

The Company’s strategic transformation builds on the achievement of promising preclinical proof-of-concept for its lead candidate programs, .HEAL-101 and .HEAL-201. .HEAL-101 is an in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia and .HEAL-201 is an in vivo epigenetic editing product candidate targeting PCSK9 for severe hypercholesterolemia.

.HEAL-101

• Severe hypertriglyceridemia (sHTG) remains a significant unmet medical need, with affected patients facing a high risk of acute pancreatitis, an increased burden of cardiovascular disease, and limited treatment options. .HEAL-101 is being developed for patients with high-risk sHTG, including those with triglyceride levels ≥880 mg/dL or ≥500 mg/dL with a history of acute pancreatitis, representing an estimated target population of approximately 1 to 2 million patients across the United States and Europe.
• .HEAL-101 targets the human APOC3 gene, a well-validated target for sHTG, via a TALE-base editor specific to the APOC3 gene (“APOC3 TALEB”) formulated in Lipid Nanoparticles (LNP).
• The APOC3 TALEB displayed high on-site base editing activity when transfected as mRNA in a hepatic cell line (mean base editing >70%) and base editing translated into a deep and significant reduction of APOC3 protein secretion (mean reduction >70%). APOC3 TALEB displayed a highly specific base editing profile using an unbiased, genome wide off-site identification method.
• Intravenous injection of .HEAL-101 in a liver humanized normolipidemic murine model successfully edited human APOC3 (mean on-site base editing ~55%) and decreased plasmatic APOC3 levels (mean decrease ~60%; up to 70%), associated with a decrease of circulating triglycerides (mean decrease ~45%; up to 68% with respect to pre-treatment baseline). It did not significantly increase the level of liver ALT (alanine aminotransferase) compared to untreated control.
• Intravenous injection of .HEAL-101 in a hypertriglyceridemic humanized APOC3 transgenic murine model significantly decreased plasmatic APOC3 levels (mean decrease ~70%) and triglyceride levels (means decrease ~76%) compared to pre-treatment baseline, demonstrating the efficacy of .HEAL-101 in a relevant disease model.
• The Company plans to initiate a Phase 1 investigator-initiated trial (IIT) in China and share the preliminary clinical data from this program in H2 2027.

.HEAL-201

• Severe hypercholesterolemia remains a major driver of atherosclerotic cardiovascular disease, with many high-risk patients continuing to experience elevated low-density lipoprotein cholesterol (LDL-C) levels despite currently available therapies. This burden is particularly significant among younger high-risk patients with severe genetic forms of hypercholesterolemia and those with premature cardiovascular disease, representing an estimated 1 to 2 million patients across the United States and Europe. .HEAL-201 is being developed to address the needs of these high-risk patient populations.
• .HEAL-201 targets the human PCSK9 gene, a well-validated target for severe hypercholesterolemia, via a TALE-epigenetic modulator specific to the promoter of PCSK9 (“PCSK9 TALEM”) formulated in LNP to treat severe hypercholesterolemia.
• The PCSK9 TALEM displayed a high on-site epigenome editing activity when transfected as mRNA in a hepatic cell line (mean base editing >90%). Epigenome editing translates into a stable, deep and significant reduction of PCSK9 transcript levels and PCSK9 secretion without evidence for off-site gene and protein modulation.
• Intravenous injection of PCSK9 TALEM mRNA LNPs in a liver humanized murine model, successfully decreased plasmatic levels of PCSK9 (mean >90%).
• The Company plans to initiate a Phase 1 IIT in China and share the preliminary clinical data from this program in H1 2028.

Cellectis’ differentiated gene editing platform

Cellectis’ core competencies encompass nuclease editing, base editing, epigenetic editing and transcriptional regulation. While most gene editing companies focus on a single editing modality, Cellectis’ broad gene editing toolbox built over a quarter century allows for a combination of therapeutic targets utilizing several gene editing modalities.

André Choulika, Ph.D., Co-Founder and Chief Executive Officer of Cellectis, commented: “Gene surgery has the potential to transform the treatment of high-risk metabolic diseases by delivering long-lasting benefits through a single IV injection. Our decision to focus Cellectis on in vivo Gene Editing reflects the progress we have made with .HEAL-101 and .HEAL-201 and our assessment of where our gene editing capabilities can be most effectively deployed. These programs use two distinct approaches from our platform, base editing of APOC3 and epigenetic editing of PCSK9, which are designed to provide highly specific genomic or epigenomic modulation with the goal of avoiding double-strand DNA breaks. They have generated encouraging preclinical proof-of-concept and our priority is now to advance both programs toward the clinic and generate first-in-human data.”

Lasme-cel and eti-cel

In 2026, despite our continued conviction in the promise of allogeneic CAR T-cell therapies and strong physician interest in lasme-cel and eti-cel, the commercial and clinical landscape for B-ALL and NHL changed materially. Continued and recently accelerated advances in frontline treatment regimens have lowered relapse rates, reducing the number of patients progressing to later lines of therapy. Concurrently, the rapid emergence of bispecific antibodies and in vivo CAR-T approaches has intensified competition in second and third-line treatment settings. Together, these dynamics have reduced the addressable patient population for lasme-cel and eti-cel, resulting in slower enrollment, a potentially longer and more costly development pathway, and therefore a delayed timeline to potential registration. We believe these trends are likely to continue and further constrain the commercial opportunity for both product candidates.

After a thorough assessment of the evolving therapeutic landscape and strategic review, the Company has determined that the most effective use of its financial and operational resources is to focus on and accelerate the advancement of its most promising in vivo gene editing assets. Cellectis will therefore exit the development of lasme-cel and eti-cel, while seeking strategic partnering opportunities to maximize their value.

Operational realignment to the new strategic direction

The Company will realign its organization¹ and resources to focus on its in vivo Gene Editing pipeline and support its existing cell therapy partnerships with AstraZeneca, Allogene, Servier and Iovance. These combined actions are being designed to extend the Company’s cash runway into H2 2028², providing financial flexibility to advance Cellectis’ in vivo Gene Editing pipeline through key development milestones.

Conference Call

The Cellectis management team will host a conference call and webcast on September 14, 2026:

• English-language at 8:00 a.m. ET.
  Webcast link:
  https://viavid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480
  Phone number: +1-800-717-1738 or +1-646-307-1865

• French-language at 9:00 a.m. ET.
  Webcast link:
  https://viavid.webcasts.com/starthere.jsp?ei=1775361&tp_key=2968b7b0ca
  Phone number: +1-800-717-1738 or +1-646-307-1865

A replay will be available on the Company’s website, under the Investors section “Events & Webcasts” following the event.

In this context, the trading of Cellectis’ ordinary shares on the regulated market of Euronext Growth market of Euronext Paris will be temporarily halted, at the Company’s request, on Monday September 14, 2026 from the opening of the market at 9:00 a.m. CET until the opening of the Nasdaq Global Market at 3:30 p.m. CET.

About Cellectis

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment. Leveraging decades of expertise in programmable DNA-binding proteins, the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generation of genetic medicines designed to move beyond disease management and toward lasting therapeutic impact.

Cellectis’ headquarters are in Paris, France, with locations in New York, and Raleigh (NC). Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

Cautionary Statement

This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “believe,” “can,” “design”, “encouraging,” “expect”, “into”, “moving forward”, “plan”, “potential”, “promising,” “target”, “will”, or similar expressions and/or the negative of these. These forward-looking statements are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements in this press release include statements regarding the Company’s transition into an in vivo gene editing company, the ability of the Company to initiate a IIT in China, the planned timing for the release of first-in-human data for the Company’s lead programs, the potential for success of the Company’s in vivo gene editing programs, the ability to continue advancement of cell therapy activities through existing partnerships, the ability to partner lasme-cel and/or eti-cel, the anticipated impact, including potential cost savings, of the Company’s decision to cease the development of lasme-cel and eti-cel and to initiate a restructuring plan, the contemplated implementation of headcount reductions and other cost-savings initiatives and their planned timeframe, and the targeted extension of the Company’s cash runway. Actual results, performance or events may differ materially from those projected in any forward-looking statement. Many important factors may adversely affect such forward-looking statements and cause actual results to differ from those in any forward-looking statement, including, without limitation, uncertainties inherent in the initiation and completion of preclinical and clinical studies; the availability and timing of results from studies, once initiated; the acceptance by global regulatory agencies of data generated from IIT in China; the potential that pre-clinical animal model data may not translate into further preclinical development or clinical setting; promising preclinical data not yielding positive further preclinical data or clinical results; the performance of the IIT in China, changes in the competitive landscape for in vivo gene editing products; expectations for regulatory approvals to conduct clinical trials; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; and impacts of the Company’s headcount reductions and other cost savings initiatives, which may include operational and strategic challenges. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2025 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC’s website at www.sec.gov, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

For further information on Cellectis, please contact:

Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com        
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

_____________________________
¹ Subject to the completion of the relevant works council consultation process and applicable US & French labor law requirements.

² Excluding any impact from the potential future partnering of lasme-cel and/or eti-cel.

Attachment

• Mr. ZOGS PR EN (1)

COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since the last announcement of transactions on September 7, 2026, the following transactions have been made by Nordea on behalf of Bavarian Nordic:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated until September 7, 2026	132,715	219.26	29,099,679
September 7, 2026	48,000	211.67	10,159,992
September 8, 2026	24,210	210.13	5,087,315
September 9, 2026	60,000	203.63	12,217,968
September 10, 2026	10,000	203.32	2,033,170
September 11, 2026	8,510	203.64	1,732,937
Accumulated under the program	283,435	212.86	60,331,061

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

Following these transactions, Bavarian Nordic holds a total of 3,842,026 treasury shares, corresponding to 4.85% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Company Announcement no. 42 / 2026

Attachments

• Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
• Appendix with detailed transaction data

Kelly Beaver accelerates the execution
of the Horizons strategic plan

Paris, September 14, 2026 – During an investor presentation to be held today, Kelly Beaver, Chief Executive Officer of Ipsos, will provide an update on “Horizons”.

Appointed Chief Executive Officer of Ipsos on July 30, 2026, Kelly Beaver confirms “Horizons”, the strategic plan developed since early 2025 and presented at the Investor Day last January. This plan is built around six pillars: Growth of our global solutions, Strong local presence, Speed, Artificial intelligence, Access to real people, Data integration and analytics.

The priority now is to accelerate its execution to drive Ipsos’ growth.

Kelly Beaver, Chief Executive Officer of Ipsos, stated: “More than ever, our clients need reliable and timely information to understand their markets and make the right decisions. This represents a structural opportunity for Ipsos.

Horizons is the right strategy. Our priority now is to accelerate its execution and translate it into results more quickly, particularly as our performance since the beginning of the year has fallen short of our ambitions.

I am confident in our ability to deliver because we have unique strengths: talented and highly engaged teams, a global presence, deep multi-specialist expertise, access to high-quality data, and strong capabilities in technology and artificial intelligence.

I am proud to launch our new corporate campaign, Augmented Ipsos:
Augmenting Speed, Augmenting Insights, Augmenting Trust
To turn complexity into clarity. And clarity into impact.”

***

As of August 31, organic growth in the order book stood at 1.2%, stable compared with the end of June. Organic revenue growth was 1.1%, compared with 0.8% at the end of the first half.

The Q3 2026 results presentation will take place on 23 October at 8:30 a.m. CET.

Our beliefs underpinning our new communication campaign:

The world is moving … faster than ever. Markets evolve. Behaviours change. Opinions shift. Access to data and information has never been easier. Yet, for our clients, making decisions has never been

more complex.

Better decisions start with better data. Data has to be collected. Analysed. Verified. It needs scientific rigour to become truly reliable.

At Ipsos, we predict what comes next by continually evolving how we decode the world. It’s how we’ve helped clients, with our multi-specialist services, to navigate change for more than 50 years.

As Artificial Intelligence unlocks new possibilities, Ipsos’ experts in 90 countries are helping turn data into better decisions.

Expanding the reach of research, connecting data in new ways, and pushing analysis further and faster. Delivering insights that matter across society, markets and people.

At the heart of Ipsos are our people and we provide access to millions of real people around the world.

Combining Artificial Intelligence with Human Intelligence to deliver deeper understanding and better decisions.

Augmenting Speed
Augmenting Insights
Augmenting Trust
To turn complexity into clarity. And clarity into impact.

This is what we call Augmented Ipsos.

Watch the new corporate video

ABOUT IPSOS

Ipsos is one of the largest market research companies in the world, present in 90 markets and employing nearly 20,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

“Game Changers” – our tagline – summarises our ambition to help our 5,000 clients navigate with confidence our world of rapid change.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since 1 July 1999. The company is part of the SBF 120, Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).

ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP
www.ipsos.com

35 rue du Val de Marne
75 628 Paris, Cedex 13 France
Tel. +33 1 41 98 90 00

Attachment

• Press release – 140926 – EN

Paris

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today it has been named a Leader in the QKS Group SPARK Matrix™: Accounts Payable Automation 2026 report. The SPARK Matrix evaluates accounts payable (AP) automation solution vendors based on technology excellence and customer impact, recognizing providers that deliver strong capabilities, customer value and market vision. According to QKS Group, Quadient’s leadership position reflects its ability to deliver innovative, scalable and future-ready AP automation.

“Quadient is well positioned in the AP automation market, combining AI-driven invoice processing, configurable approval workflows, multi-entity support and broad ERP integration capabilities,” said Sanjeevi Cuddalore Ramachandran, Senior Principal Analyst & Associate Vice President, QKS Group. “Its emphasis on usability and seamless integration allows finance teams to automate core AP processes, improve processing accuracy, and gain stronger operational visibility without requiring significant disruption to existing financial systems. The platform’s support for e-invoicing, multilingual and multi-currency environments, together with Quadient’s broader AP and AR automation capabilities, extends its value beyond transactional automation toward more connected financial operations and cash-flow visibility.”

Quadient’s unified approach to financial process automation was noted in the report as a key differentiator. Quadient’s software solutions have been unified into the Quadient Suite, accessible via a single point of entry and providing users with one trusted provider and a consistent experience across finance automation and customer communication solutions. As part of the Quadient Suite, the new cash dashboard capability allows for fast visibility of working capital along with AI-powered actionable insights and recommendations across AP and accounts receivable (AR).

“Middle market finance teams often face the same operational and compliance challenges of large enterprises but with fewer resources and leaner teams,” said Valérie Colin, VP Product & Strategy, Finance Automation at Quadient. “They need solutions that improve cash flow visibility, help them get control over their spend and accelerate invoices payment and collections, while reducing manual work. By bringing AP and AR automation and AI-powered cash dashboards together under a unified experience, Quadient is helping customers improve efficiency and make better financial decisions. We’re honored that QKS Group recognizes Quadient’s differentiated approach and the outcomes it delivers for our customers.”

Quadient AP helps B2B organizations automate the processing of suppliers’ invoices, approvals, and purchasing activities while supporting a growing number of e-invoicing compliance requirements across European markets. The SPARK Matrix report also recognized Quadient AP’s broad integrations with leading ERP and accounting platforms such as Oracle NetSuite, Sage, Sage Intacct, Microsoft Dynamics GP, QuickBooks, Acumatica and Xero.

For more information about Quadient’s financial automation solutions, visit www.quadient.com.

About Quadient
Quadient designs and builds human-centered, AI-driven automation solutions for business communications. Our software empowers hundreds of thousands of customers to create, deliver, and manage world-class communications with speed and ease. From financial automation and customer communications to mail and parcel management, Quadient reduces friction and waste so customers can focus on growth and customer connections. Quadient is listed on Euronext Paris (QDT) and part of the CAC® Mid & Small and CAC Technology indexes. Make room for the remarkable at quadient.com.

Contacts
Quadient
Joe Scolaro
+1 203-301-3673
j.scolaro@quadient.com  

Walker Sands
Kiley Ribordy
quadientpr@walkersands.com   

Attachment

• PR SPARK Matrix for AP 2026 – EN – Final

TORONTO and PERTH, Western Australia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Cygnus Metals Limited (ASX: CY5; TSXV: CYG; OTCQB: CYGGF) (“Cygnus” or the “Company”) refers to the proposed transaction under which Central Asia Metals PLC (AIM: CAML) (“CAML”) will acquire 100% of the shares in Cygnus pursuant to a scheme of arrangement under Part 5.1 of the Corporations Act 2001 (Cth) (“Scheme”).

Capitalised terms in this announcement that are not otherwise defined have the meanings given to them in the Scheme Booklet dated 13 August 2026 (“Scheme Booklet”).

Scheme Meeting reminder

As outlined in the Scheme Booklet, the Cygnus shareholder meeting to approve the Scheme (“Scheme Meeting”) is scheduled to take place at the offices of Hamilton Locke at Level 39, 152-158 St Georges Terrace, Perth WA 6000 at 2.00pm (AWST) on 18 September 2026. All Cygnus Shareholders registered on the Cygnus Register at 5.00pm (AWST) on 16 September 2026 will be entitled to vote at the Scheme Meeting.

All Cygnus Shareholders are encouraged to vote either by attending and voting at the meeting or lodging a proxy vote ahead of the meeting. Further details on how to vote are set out in the Scheme Booklet.

Conditions Precedent update

As detailed in the Scheme Booklet, there are several Conditions Precedent which need to be satisfied or waived (if applicable) before the Scheme can be implemented. As previously announced:

• North Macedonian merger clearance has been obtained by CAML;
• the Independent Expert’s opinion is that the Scheme is fair and reasonable and hence in the best interests of Cygnus Shareholders in the absence of a superior alternative proposal emerging; and
• CAML Shareholders have approved the resolution to allot the New CAML Shares pursuant to the Scheme.

Further, and while not a condition precedent to the Scheme, the Toronto Stock Exchange (“TSX”) has conditionally approved the listing on the TSX of the shares in CAML, including the New CAML Shares that will be issued to Cygnus Shareholders pursuant to the Scheme.

The Kazakhstan regulatory approval condition precedent is in process, with the statutory timetable now requiring a decision by no later than Thursday, 1 October 2026. As a result, this approval may not be obtained prior to the Scheme Meeting or potentially the current Second Court Date (presently scheduled for 23 September 2026). Should the approval not be received before the Second Court Date, Cygnus may either apply to the Court to defer the Second Court Date to the earliest practicable date following receipt of the Kazakhstan regulatory approval and/or seek the Court’s approval to treat the Kazakhstan regulatory approval as a condition subsequent. CAML has advised Cygnus that it is not aware of any specific reason why the Kazakhstan regulatory approval will not be received in the ordinary course. It is worth noting that CAML has a successful track record of receiving a similar style of government approvals in Kazakhstan.

Further, Cygnus is not aware of any reason why any of the other outstanding conditions to the Scheme will not be satisfied or waived in the ordinary course prior to the current Second Court Date.

Recommendation of the Cygnus Directors

Each of the Cygnus Directors recommends that Cygnus Shareholders vote, and intends to vote any shares they own or control, in favour of the Scheme at the Scheme Meeting, each in the absence of a Superior Proposal and subject to the Independent Expert continuing to conclude that the Scheme is in the best interests of Cygnus Shareholders.

This announcement is authorised for release by the Board of Cygnus Metals Limited.

David Southam Executive Chair T: +61 8 6118 1627 E: info@cygnusmetals.com	Nicholas Kwong President & CEO T: +1 418 748 5076 E: info@cygnusmetals.com	Media: Paul Armstrong Read Corporate T: +61 8 9388 1474

About Cygnus Metals

Cygnus Metals Limited (ASX: CY5, TSXV: CYG, OTCQB: CYGGF) is a diversified critical minerals exploration and development company with projects in Quebec, Canada and Western Australia. The Company is dedicated to advancing its Chibougamau Copper-Gold Project in Quebec with an aggressive exploration program to drive resource growth and develop a hub-and-spoke operation model with its centralised processing facility. In addition, Cygnus has quality lithium assets with significant exploration upside in the world-class James Bay district in Quebec, and REE and base metal projects in Western Australia. The Cygnus team has a proven track record of turning exploration success into production enterprises and creating shareholder value.